{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:18:24Z","timestamp":1783196304528,"version":"3.54.6"},"reference-count":47,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association between outcomes and BMF changes. We present BMF data from Janus kinase (JAK) inhibitor\u2013naive patients from SIMPLIFY\u20101 (NCT01969838), a double\u2010blind, randomized, phase 3 study of momelotinib vs ruxolitinib. Baseline and week 24 bone marrow biopsies were graded from 0 to 3 as per World Health Organization criteria. Other assessments included Total Symptom Score, spleen volume, transfusion independence status, and hemoglobin levels. Paired samples were available from 144 and 160 patients randomized to momelotinib and ruxolitinib. With momelotinib and ruxolitinib, transfusion independence was achieved by 87% and 44% of patients with BMF improvement of \u22651 grade and 76% and 56% of those with stable\/worsening BMF; there was no association between BMF changes and transfusion independence for either arm (momelotinib, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.350; ruxolitinib, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.096). Regardless of BMF changes, hemoglobin levels also generally increased on momelotinib but decreased on ruxolitinib. In addition, no associations between BMF changes and spleen (momelotinib, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.126; ruxolitinib, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.407)\/symptom (momelotinib, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.617; ruxolitinib, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.833) outcomes were noted, and no improvement in overall survival was observed with \u22651\u2010grade BMF improvement (momelotinib, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.395; ruxolitinib, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.407). These data suggest that the anemia benefit of momelotinib is not linked to BMF changes, and question the use of BMF assessment as a surrogate marker for clinical benefit with JAK inhibitors.<\/jats:p>","DOI":"10.1002\/jha2.854","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T08:07:49Z","timestamp":1707293269000},"page":"105-116","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-5400","authenticated-orcid":false,"given":"Stephen T.","family":"Oh","sequence":"first","affiliation":[{"name":"Division of Hematology Washington University School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medicine, Princess Margaret Cancer Centre University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Cellular Therapy, and Hemostaseology University of Leipzig Medical Center  Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Devos","sequence":"additional","affiliation":[{"name":"Microbiology, and Immunology, Laboratory of Molecular Immunology (Rega Institute) Department of Hematology, University Hospitals Leuven and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, AP\u2010HP, Ho\u0302pital Saint\u2010Louis, Centre d\u2019Investigations Cliniques  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-091X","authenticated-orcid":false,"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[{"name":"Department of Haematology Guy's and St Thomas\u2019 NHS Foundation Trust and University College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-7093","authenticated-orcid":false,"given":"Andrew","family":"Perkins","sequence":"additional","affiliation":[{"name":"Australian Centre for Blood Diseases Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Haematology Vall d'Hebron University Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[{"name":"Centre for Medical Education Queen's University  Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Mead","sequence":"additional","affiliation":[{"name":"MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine NIHR Biomedical Research Centre University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-5880","authenticated-orcid":false,"given":"Miklos","family":"Egyed","sequence":"additional","affiliation":[{"name":"Department of Hematology Somogy County Kaposi M\u00f3r General Hospital  Kaposv\u00e1r Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology Masaryk University and University Hospital Brno  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7207-6595","authenticated-orcid":false,"given":"Tomasz","family":"Sacha","sequence":"additional","affiliation":[{"name":"Department of Hematology Jagiellonian University Hospital  Krak\u00f3w Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Sierra Oncology, a GSK company  San Mateo California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Huang","sequence":"additional","affiliation":[{"name":"Sierra Oncology, a GSK company  San Mateo California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Strouse","sequence":"additional","affiliation":[{"name":"Sierra Oncology, a GSK company  San Mateo California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center Wake Forest University School of Medicine  Winston\u2010Salem North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01116-z"},{"issue":"2","key":"e_1_2_13_3_1","first-page":"121","article-title":"Myelofibrosis: clinicopathologic features, prognosis, and management","volume":"16","author":"O'Sullivan JM","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16576"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34205"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.141283"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554634"},{"key":"e_1_2_13_9_1","first-page":"89","article-title":"Myelofibrosis\u2010associated complications: pathogenesis, clinical manifestations, and effects on outcomes","volume":"7","author":"Mughal TI","year":"2014","journal-title":"Int J Gen Med"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0954-2"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000204873"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2864"},{"key":"e_1_2_13_13_1","volume-title":"Jakafi (ruxolitinib) [package insert]","author":"Incyte","year":"2023"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26935"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)01439-2"},{"key":"e_1_2_13_16_1","volume-title":"Inrebic (fedratinib) [package insert]","author":"BMS","year":"2023"},{"key":"e_1_2_13_17_1","volume-title":"Vonjo (pacritinib) [package insert]. CTI BioPharma Corp.","author":"CTI","year":"2023"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0527-7"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000424"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00392-1"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1358"},{"key":"e_1_2_13_26_1","volume-title":"Ojjaara (momelotinib) [package insert]","author":"GSK","year":"2023"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02036-0"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.116"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.11.004"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.683401"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0236-2"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.87"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-0042-8"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02188"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02864"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00116-8"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0302-9"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0869-8"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002662"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740092"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095109"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0585-5"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002230"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159409"}],"updated-by":[{"DOI":"10.1002\/jha2.934","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000}}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T16:48:39Z","timestamp":1708706919000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1002\/jha2.854"],"URL":"https:\/\/doi.org\/10.1002\/jha2.854","archive":["Portico"],"relation":{"correction":[{"id-type":"doi","id":"10.1002\/jha2.934","asserted-by":"object"}]},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2023-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}